volume 26, issue 7-8, P393-400 2018
DOI: 10.1007/s12471-018-1126-0
View full text
Sign up to set email alerts

Abstract: ObjectiveTo investigate 1‑year outcomes with routine prasugrel treatment after acute coronary syndrome (ACS) in a large-scale registry.MethodsThe Rijnmond Collective Cardiology Research registry is a prospective, observational study that enrolled 4,258 consecutive ACS patients treated with percutaneous coronary intervention (PCI) with 1‑year follow-up. Patients received prasugrel as first-choice antiplatelet agent, except for increased bleeding risk patients in which clopidogrel was recommended. Events were va…

Expand abstract